Market Research Blog

Leading players in the biotechnology and pharmaceutical sectors along with research institutes are now increasingly focusing on R&D activities relating to drug creation and development. Future Market Insights (FMI) in a new study has forecast the global pharmaceutical intermediates to reach US$ 30 Bn in 2020, with the market predicted to exhibit a CAGR of 4% during the forecast period (2020-2030)

Pharmaceutical intermediates are used in during manufacturing of bulk drugs as raw materials. These are the material produced during the synthesis of an active pharmaceutical ingredient (API). However, pharmaceutical and biotech companies can make use of these drug intermediates for the purposes of research and development (R&D). Moreover, there are different forms of pharmaceutical intermediates available such as high quality pharmaceutical intermediates, moderate quality pharmaceutical intermediates and premium quality intermediates. The high-quality and premium pharmaceutical intermediates are mainly used for R&D activities.

For More Information or Query or Customization Before Buying, Visit:
https://www.futuremarketinsights.com/customization-available/rep-gb-4515

COVID-19 pandemic is negatively impacting pharmaceutical intermediates sales due to supply chain disruptions caused due to extended period of lockdown. Nonetheless growth is expected to recover because an increasing number of pharma companies are engaging in research and development to find effective treatment and vaccination for COVID-19 virus.

Key Takeaways from Pharmaceutical Intermediates Marker Study

• The demand for chiral intermediates will continue rising through the forecast period
• East Asia will dominate in the global pharmaceutical intermediates market. China is expected to emerge as the most lucrative market for pharmaceutical intermediates in the region.
• Analgesics to remain primary application, expanding at Y-o-Y rate exceeding 6% through 2020
• The demand for Generic Drug Intermediates is expected to be higher than Branded Drug Intermediates
• Biotech and Pharma Companies will continue exhibiting high demand for pharmaceutical intermediates

“Rising drug development activities worldwide as well as increasing adaption of pharmaceutical intermediates as raw material are driving the growth of global Pharmaceutical Intermediates market” says the FMI Analyst

Ask Us Your Questions About This Report:
https://www.futuremarketinsights.com/ask-question/rep-gb-4515

Acquisitions, Partnerships and expansion are key Strategic Focus of Pharmaceutical Intermediates Market Players

Leading players in the Pharmaceutical Intermediates market on strengthening their market position though the Acquisition, Partnerships and expansion. For Instance,

• On April 2018, strategic collaboration between Porton Pharma Solutions, Ltd. And Codexis, Inc. to use Codexis’ biocatalyst technology within Porton’s global custom active pharmaceutical ingredients (API) and intermediate for manufacturing business.
• On June 2017, BASF SE is expanding its production capacity at Texas site, whereas it is also constructing new Ibuprofen API facility in Ludwigshafen, Germany, which is expected to be functional in 2021.

Key Participant Insights

The global market is set to expand its scope in the forecast period, due to rising prevalence of chronic disease globally and adoption of Pharmaceutical Intermediates at various stages of drug development by pharmaceutical manufacturers. In addition to this, cost effectiveness and rise in alternate methods for purification of oligonucleotide has augmented the sales of Pharmaceutical Intermediates.

The key market players covered by FMI include Chiracon GmbH, Aceto Corporation, Midas Pharma GmbH, Codexis, Lianhe Chemical Technology Co., Ltd, Sanofi S.A, Dishman Group And BASF SE, And Chemcon Speciality Chemicals Pvt. Ltd consolidating their positions through mergers, acquisitions and new product launches.

Empty capsule manufacturers are progressively targeting specialty markets such as contract manufacturers, generic manufacturers, and pediatric drug manufactures. Increasing penetration of low-cost manufacturers in various countries, and supply contracts of life-saving essential drugs, primarily in developing and emerging countries, are further driving the empty capsules market.

The global empty capsules market is estimated to be valued at US$ 1.9 Bn in 2020, with the market expected to exhibit a CAGR of 8% during the forecast period (2020-2030). The coronavirus (COVID-19) pandemic that has so far claimed the lives of over 200,000 people and infected over 3 million, has forced several countries to declare nationwide lockdowns. This has disturbed supply chains in the empty capsules market, due to logistics paralysis. As such, the market is expected to witness a gradual decline in in 2020.

“Lower labour cost and abundant availability of raw materials are among the key factors driving the empty capsules market in Asia Pacific excluding Japan (APEJ) and Western Europe. In addition, favorable regulatory ecosystem to establish empty capsule manufacturing businesses and lower taxation policies are propelling market growth in APAC.”

For More Information or Query or Customization Before Buying, Visit:
https://www.futuremarketinsights.com/customization-available/rep-gb-782

Key Takeaways of Empty Capsules Market Study

• Greater focus on relieving pressure of supply chain due to demand gap is being tackled by ramping up production capacity; up-scaling is the fundamental strategy outlined for meeting demand in the empty capsules market.
• Vegetable capsules are the latest innovation and are expected to replace gelatin-based variants. Recently, hard gelatin manufacturers have begun increasing the production of vegetarian capsules at scale.
• South and East Asian pharmaceutical markets are expected to grow at twice the global average in terms of value, owing to population growth, rising incomes, and improved access to healthcare.
• The empty capsules market in China is anticipated to exhibit the fastest growth, where per capita spending is anticipated to increase by over 70% in the coming five years.
• High upfront costs and lower margin levels in empty capsules have resulted in 10%-20% price hike in finished products, registering lower sales for animal-based gelatin products in the recent past.
• India, with almost 40% growth, is offering value-capture opportunities, owing to good patient recruitment, acceptable quality of services, reasonable cost-quality ratio, existence of regulatory agencies, high standards of care, larger population base, and low cost of labour.
• Companies manufacturing halal capsules are obtaining halal certification from the Islamic Food and Nutrition Council of America (IFANCA) to capture market shares in Muslim-dominated countries.
• The empty capsules market is consolidated, with leading manufacturers holding around 70% revenue share. Further, growing prominence of CMOs and large-scale gelatin manufacturers is anticipated to boost the growth engine.
• Higher volume handling by key players in comparison with local manufacturers, and higher production capabilities and price advantages over non-standard manufacturers, are expected to generate significant revenue pockets.

Ask Us Your Questions About This Report:
https://www.futuremarketinsights.com/ask-question/rep-gb-782

Key Players Focus on Capacity Expansion, Strategic Acquisitions, and Joint Ventures to Widen Regional Presence

Leading players in the empty capsules market, such ACG Worldwide, Capsugel, Qualicaps, Inc., Bright Pharma Caps, Inc., and Roxlor LLC, are concentrating on business expansion through mergers, joint ventures, distribution agreements, and capturing untapped market potential.

• For example, in 2015, Capsugel increased the production of vegetarian-based capsules by investing US$ 25 Mn across its manufacturing sites.
• Empty capsule manufacturers are generating high returns from nutraceutical and pharmaceutical industries by supplying non-animal or vegetarian empty capsules, with effective physical properties such as reduced moisture content, best suited for nutrient supplements and hygroscopic drugs.
• In similar context, empty capsule manufacturers are boosting substantial sales revenue from nutraceutical manufacturers by supplying vegetarian-based empty capsules coupled with fluid filling technology.
• Top manufacturers of hard gelatin capsules are expanding their production facilities through acquisitions.
• For instance, Qualicaps completed the acquisition of Genix Industria Farmaceutica Ltd., one of Brazil’s top hard empty capsule manufacturers. The acquisition permits the manufacturer to establish its operating sites in the U.S., Canada, Spain, Japan, and Romania.

The global surface plasmon resonance market is projected to reach a market value of US$ 770 Mn in 2019, increasing at a decent CAGR of 6% over the forecast period of 2019 – 2029.

“Increasing application of surface plasmon resonance in the field of drug discovery and medical imaging is contributing to the growth of the surface plasmon resonance market. Development of new technologies coupled with surface plasmon resonance, such as nanoparticle surface plasmon resonance and microfluidics, is playing an important role in the overall growth of the global surface plasmon resonance market.”

Key Takeaways of Surface Plasmon Resonance Market Study

• The market share of imaging systems is evaluated to grow at a significant rate by the end of 2029, as these are the ideal solution for the analysis of label-free and multiplexed biomolecules.
• Sales of surface plasmon resonance are envisaged to be higher in North America. Increasing adoption of imaging systems and biosensors in life science R&D is anticipated to boost the growth of the surface plasmon resonance market in the region.
• Innovation while developing imaging software used in surface plasmon resonance for the analysis of kinetic parameters of biomolecular interactions is a key aspect for increasing the reproducibility of results. Companies are investing in R&D initiatives to introduce superior imaging devices with enhanced magnification, to observe the smallest deflection in the refractive index, thus aiding the growth of the surface plasmon resonance market.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-962

Adoption of Label-free Detection Technique for Analysis of Biomolecules

Detection of biological analytes through their physical properties is difficult. As a result, researchers rely on the addition of some sort of label to one or more of the analytes that need to be studied. Inclusion of this label for increasing specificity and accuracy has increased the cost of reagents and assays. To reduce assay cost and complexity while providing more qualitative information through labelled detection, adoption of the label-free detection technique such as surface plasmon resonance has increased, and is expected to fuel the growth of the global surface plasmon resonance market during the forecast period. The label-free detection technique simplifies the procedure by reducing the time and effort required for the development of the assay. Thus, increasing adoption of label-free detection techniques over labelled detection is expected to boost the growth of the global surface plasmon resonance market.

Want more insights?

The surface plasmon resonance market report, a new study by Future Market Insights, opines on the evolution of the global surface plasmon resonance market from 2014–2018, and presents demand projections for 2019–2029, on the basis of product type (imaging systems, sensor systems, and reagents), application (drug delivery, material science, and biosensors), and end user (academic and research institutes, food and beverage industry, biopharmaceutical companies, CROs, and others), across seven prominent regions.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-962

SURFACE PLASMON RESONANCE MARKET TAXONOMY

The global surface plasmon resonance market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Product Type

• Imaging Systems
• Sensor Systems
• Reagents

Application

• Drug Discovery
• Material Science
• Biosensors

End User

• Academic & Research Institutes
• Food & Beverage Industry
• Biopharmaceutical Companies
• CROs

Others

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-962

Region

• North America
• Latin America
• Western Europe
• Eastern Europe
• APEJ
• Japan
• Middle East and Africa

The report opines that the outbreak of COVID-19 is likely to create short-term fluctuations on the supply side due to pandemic-related issues such as workforce shortages and disruptions of delivery networks. Similarly, a steep decline in the number of tests has been observed during the pandemic, and this is expected to further decelerate the demand for PD-L1 biomarker testing.

The report primarily attributes the growth of the market to the increasing incidence of cancers, especially lung and skin, coupled with the development of advanced diagnostic kits and assays.

Likewise, rising awareness regarding the availability of testing methodology such as immunohistochemistry-based assays and Enzyme-linked Immunoassay (ELISA) based detection will continue to impel the adoption of PD-L1 biomarkers in the forthcoming years.

Key Takeaways

• The global PD-L1 biomarkers testing market is expected to surge past valuation of US$ 2.05 Bn by the end of the forecast period.
• PD-L1 SP142 assay kits will remain the most popular products among end-users, capturing nearly half of the market value, owing to high efficiency in detecting cancer tumors.
• Non-small cell lung cancer and melanoma are cumulatively expected to hold more than 50% of the total market value on the back of the soaring prevalence of these diseases.
• By end-use, PD-lL1 biomarker testing finds the majority of applications in hospitals, which is expected to account for over 60% of market value.
• North America will spearhead the regional landscape through the forecast period, accounting for more than 50% of the global market value.
• Europe is poised to remain the second most lucrative region, holding nearly 1/3rd of market value.

“Market players are directing their efforts towards improving the accessibility of these products and are marking them cost-effective to ensure wide-scale adoption,” remarks FMI analyst.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-5897

COVID-19 Impact on PD-L1 Biomarker Testing Market

The COVID-19 pandemic has created disruptions across the healthcare technology landscape and has resulted in a shifting preference among manufacturers towards essential technologies and treatments. Furthermore, although PD-L1 biomarker testing is used to test severe diseases such as cancer, a reduced number of screenings is adversely impacting the demand for testing.

For instance, according to trends observed by Cancer Research Network, screening rates of melanoma plummeted by approximately 50% in the UK in the past few months. Likewise, in the US, the number of tests conducted to detect non-small cell lung cancer fell by 30% in March as compared to February. As patients reschedule or skip regular screenings, this is creating a downtrend in demand for PL-D1 biomarker testing.

However, considering the severity of these diseases, the need for testing will swiftly arise in the future, ensuring that the market’s growth trajectory remains intact.

Who is Winning?

Key players operating in the market are focusing on enhancing existing product designs and developing novel products with increased accuracy. Moreover, traditional growth strategies such as acquisitions and mergers have been identified as strategies adopted by players to strengthen their foothold in the competitive landscape.

• In January 2019, Abcam Plc acquired Calico Biolabs with an objective to expand its custom monoclonal production service capabilities.
• In December 2018, NeoGenomics, Inc. acquired Genoptix, Inc. to improve its oncology diagnostic services.

FMI’s report includes profiles of some of the most prominent names in the market including F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., NeoGenomics Laboratories, Inc, HalioDx and Abcam plc. among others.

To Know More About PD-L1 Biomarkers Market

A new market research report published by Future Market Insights (FMI) on the global PD-L1 biomarkers market offers an executive-level blueprint of the market. It offers insights into demand trends and provides analysis of opportunities over the forecast period, 2020-2030. The report examines the market through four different segments – product, indication, end-use, and region. The report also provides extensive assessment of pricing by different key market dynamics, life cycle analysis, and technologies that are being deployed in the supply and product adoption across several end-use industries.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-5897

Key Segments

Product:

• PD-L1 22C3 Assay Kit
• PD-L1 28-8 Assay Kit
• PD-L1 SP142 Assay Kit
• PD-L1 SP263 Assay Kit

Indication:

• Non-small Cell Lung Cancer (NSCLC)
• Melanoma
• Renal Cell Carcinoma
• Gastrointestinal Tract Malignancies
• Ovarian Cancer
• Hematological Malignancies

End-user:

• Hospitals
• Diagnostic Laboratories
• Specialty Clinics

Region:

• North America
• Latin America
• Europe
• South Asia
• Oceania
• East Asia
• Middle East and Africa

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-5897

Advancements in consumer touch points and supply chains, including e-commerce, convenience stores and retail stores have greatly altered the prescription delivery services landscape. Advancements such as drone-based delivery and tracker based prescriptions are helping usher in smooth customer experience.

Furthermore, advanced prescription delivery systems have not only assisted in providing round-the-clock customer services but also helped manage dosage, therapy adherence and provide feedback to clinicians.

Prescription Delivery Services Market- Key Takeaways

• Diabetic prescription drugs to hold major sway, poised to capture 36.7% market share by 2030
• Ease of access to drugs addressing chronic conditions is slated to drive retail pharmacy growth to greater heights
• North America to expand stupendously at a CAGR of 18.4% from 2020-2030, attributed to the presence of multiple convenience and pharmacy stores
• Global prescription delivery services market to reach US$ 434.3 Mn by 2030-end

“Adoption of self-checkout kiosks and medicine dispensing machines shall enhance medicine purchasing experience of customers, permitting vendors to experience greater customer loyalty,” concludes the FMI analyst.

COVID-19 Impact Insights

The COVID-19 pandemic has generated fertile ground for the prescription delivery services market. The imposition of nationwide lockdowns to enforce social distancing have reduced footfalls across conventional pharmacies. This has compelled patients to rely on online retail platforms to avail their medicines.

Furthermore, heightened vulnerability of geriatrics suffering from co-morbidities to the coronavirus has necessitated stockpiling of essential medicines, thus keeping the need for prescription delivery services afloat throughout the pandemic’s duration. This panic buying behavior shall usher in an 80% y-o-y growth.

Growth is especially anticipated to be robust across the U.S, China and India, countries with the highest rates of infections. Collectively accounting for 40% of the global infection rate, these countries have witnessed an unprecedented increase in hoarding prescription medicines by individual households. This shall continue until the latter-half of 2021.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-12534

Market Witnessing Entry of e-Commerce Players

The Prescription Delivery Service Market is witnessing entry of e-Commerce, pharmacy and retail chains, albeit at a local or regional level. Technological developments, new product launches and collaborations characterize some critical expansion strategies of market players.

Some of the key players in the Prescription Delivery Service Market are: Walgreens Co., Walmart Stores Inc., CVS Health, Giant Eagle Inc., Express Scripts Holding Company, Ali Health and Kroger Co. to name a few.

Besides these established players, several startup companies are also emerging as potential game changers in the industry. These include NetMeds, Kfyao, Capsule, Myra Medicines, NURX, MedAvail, Zipdrug, Insightfil and ScriptDrop to name a few.

Walgreens, a prominent retail pharmaceutical distributor, has a robust presence in the global prescription delivery services market. The company offers refills, auto refills, drug information and home delivery services.

In 2017, the company acquired Rite Aid for a sum of US$ 5.2 billion, resulting in the merger of two of the United States’ three largest pharmacy chains.

More Insights on the Prescription Delivery Services Market

A recent market study published by Future Market Insights on the Prescription Delivery Services Market includes global industry analysis for 2015-2019 & opportunity assessment for 2020-2030, and delivers a comprehensive assessment of the most important market dynamics. The report has been segmented on the basis of disease indication (therapeutic drugs (diabetes, hypertension & cholesterol disorders), wellness supplements, OTC drugs and diagnostic drugs) and distribution channel (pharmacy stores, healthcare institutions, clinics and research institutions) across seven geographies (North America, Latin America, Europe, South Asia, East Asia, Oceania and MEA).

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-12534

Prescription Delivery Services Market Segmentation

Disease Indication

• Therapeutic Drugs
• Diabetes
• Hypertension
• Cholesterol Disorders
• Wellness Supplements
• OTC Drugs
• Diagnostic Kits

Distribution Channel

• Pharmacy Stores
• Retail Pharmacy
• Drug Stores
• Healthcare Institutions
• Clinics
• Research Institutes

Region

• North America (U.S & Canada)
• Latin America (Brazil, Mexico & Rest of Latin America)
• Europe (Germany, France, Italy, U.K, Spain, BENELUX, Russia & Rest of Europe)
• South Asia (India, Malaysia, Thailand, Indonesia & Rest of South Asia)
• East Asia (China, Japan & South Korea)
• Oceania (Australia & New Zealand)
• Middle East & Africa (GCC, Northern Africa, South Africa & Rest of MEA)

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-12534

Stool management systems are designed for bed ridden patients with fecal incontinence, a condition commonly known as bowel incontinence. These systems are used to prevent infections and reduce nursing time requirements.

The stool management systems are advantageous for older adults and patients suffering from constipation and fecal incontinence. Furthermore, it is also helpful for bed-ridden patients who may have been subject to aliments such as strokes, paralysis, or spinal injury.

According to the World Bank, approximately 700 million people were aged 65 and above in the world in 2019. Consequently, the overall high incidence of geriatric populations is resulting in the expansion of the patient pool and the resultant increase in the demand for stool management systems globally.

Fecal incontinence issues are common around the world and it has a notable burden on the economy and healthcare systems of society. The condition has impacted the economic system including hospital charges and nursing charges. Stool management systems help in reducing the nursing time and other hospital expenses.

Key players are focusing on strengthening their mergers and acquisition portfolios, in addition to advancement in technologies and new product launches. Europe holds the highest share in the market due to a vast target demographic, the presence of major market players, and high healthcare expenditure in the region.

Key Takeaways from Stool Management Systems Market Study

• Systems are key to revenue generation in the stool management systems market surpassing accessories. They are likely to account for 63% value share by the end of the forecast period.
• Luer-lock syringes will lead, with a valuation of over US$ 16 Bn by the end of 2021 owing to security in drug administration processes.
• The U.S. accounts for more than 92% share in the North America market, and will witness growth backed by presence of a well-established healthcare sector.
• Germany and France are leading countries in Europe and will account for more than 18% and 16% of the Europe market respectively in 2021.
• Australia is the largest and fastest growing market in Oceania, exhibiting 6.2% CAGR during the forecast period.

“Increasing geriatric population, technological advancements, and a rising focus on next-gen stool management systems will create lucrative growth opportunities through 2031,” says the Future Market Insights analyst.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-3568

Who is Winning?

The global stool management systems market is set to expand due to the rising number of people suffering from stool related ailments. Leading organizations within the market are set to focus on research for healthcare systems to offer increasingly effective treatment options for superior patient outcomes.

Some of the leading players in the stool management systems market include B. Braun Melsungen AG, Becton Dickinson, ConvaTec, Inc., Hollister Incorporated, Prosyn International Ltd., Consure Medical and others.

Want More Insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels that provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global stool management systems market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the stool management systems market on basis of the product type in detail, cover every aspect of the market such as systems, accessories and major regions.

Stool Management Systems Market by CategoryProduct Type

• Systems
  • External Management Systems
  • Indwelling Collection Systems
    • With Irrigation
    • Without Irrigation
• Accessories
  • Catheter Tubes
  • Luer-Lock Syringe
  • Collection Bag with Filter
  • Clinch Clamp

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3568

Region

• North America
• Europe
• Oceania